Tigo Energy Solar Rapid Shutdown Selected by Constructora San Jose for 142MWp Solar System
6.6.2024 16:00:00 EEST | Business Wire | Press release
Tigo Energy, Inc. (NASDAQ: TYGO), a leading provider of intelligent solar and energy software solutions, today announced that premier Engineering, Procurement, and Construction (EPC) firm, Constructora San Jose, S.A., has selected Tigo as the rapid shutdown technology provider for a 142MWp solar installation for an industrial ground mount in Spain. Reliable rapid shutdown functionality is essential to providing fire safety for system owners and eliminates the risk of encountering high-voltage DC electricity for operations and maintenance, as well as emergency personnel in case of contact with the system during service intervals or in emergency situations.
The system, which will produce clean energy to help serve the demand from local industry and feed excess energy back to the public grid, will include more than 107,000 Tigo TS4-A-2F MLPE devices and produce in excess of 142MWp. The project also includes more than 550 Tigo RSS Transmitters with Pure Signal technology, which eliminates disturbances in PLC signals from adjacent cable runs and improves the effectiveness of system communications functions in large and complex systems.
“With the responsibility that comes with a system of this size, the reliability and quality of Tigo was the ideal option for rapid shutdown safety,” said Diego Navarro, purchasing manager at Constructora San Jose, S.A. “In contrast to roof-mounted solar systems, the risk of contact with a ground-mounted system is somewhat higher, which is why reliable rapid shutdown is essential. With a project that will become part of the critical energy infrastructure in the region, it is important to get everything right, and the Tigo Green Glove program has provided outstanding support service throughout the process.”
The TS4-A-2F is a reliable and cost-effective two-module rapid shutdown solution that meets the latest module-level shutdown requirements, including NEC 2017/2020. The TS4-A-2F is both IEC and UL-certified for global acceptance and UL-PVRSS-certified for connectivity with the largest network of inverters. Constructora San Jose selected the TS4-A-2F to support the 670W modules used in the project, which will be under construction during the second half of 2024, with commissioning expected in the first half of 2025.
“It is an honor to have won the trust of Constructora San Jose, S.A. for this project, and we look forward to delivering on Total Quality Solar as the project moves through installation and into the operations phase,” said Mirko Bindi, Senior VP Sales EMEA & MD Europe at Tigo Energy Inc. “We design our technology to be both reliable and offer design flexibility, and this system once again shows that as system complexity and size increases, Tigo provides a great solution. The Tigo Green Glove support team will be there for the Constructora San Jose team throughout the project, with a focus on end-to-end installation quality and long-term system safety.”
The Tigo TS4 platform maximizes the benefit of PV systems for installers on all continents. With a system size range from 2kW to more than 100MW and installation in less than ten seconds per module, Tigo has a trusted and reliable product portfolio deployed around the world, from rapid shutdown to module-level monitoring and advanced energy optimization.
For more information about the Tigo TS4-A-2F MLPE device, please visit the product website here. For more information about the Tigo Green Glove program for C&I solar installers, please visit the program website here.
About Tigo Energy
Founded in 2007, Tigo is a worldwide leader in the development and manufacture of smart hardware and software solutions that enhance safety, increase energy yield, and lower operating costs of residential, commercial, and utility-scale solar systems. Tigo combines its Flex MLPE (Module Level Power Electronics) and solar optimizer technology with intelligent, cloud-based software capabilities for advanced energy monitoring and control. Tigo MLPE products maximize performance, enable real-time energy monitoring, and provide code-required rapid shutdown at the module level. The company also develops and manufactures products such as inverters and battery storage systems for the residential solar-plus-storage market. For more information, please visit www.tigoenergy.com.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20240606641822/en/
Contact information
Technica Communications
Cait Caviness
Email: tigoenergy@technica.inc
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Incyte Announces Positive CHMP Opinion for Opzelura ® (ruxolitinib) Cream for the Treatment of Adults with Moderate Atopic Dermatitis26.6.2026 14:30:00 EEST | Press release
Incyte (Nasdaq: INCY) today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has issued a positive opinion recommending the approval of Opzelura® (ruxolitinib) cream for the treatment of moderate atopic dermatitis (AD) in adult patients for whom topical corticosteroids (TCSs) and topical calcineurin inhibitors (TCIs) are inadequate or inappropriate. “AD is a chronic skin condition that can have a significant impact on daily life. The positive CHMP opinion for Opzelura marks meaningful progress toward bringing the first non-steroidal topical JAK treatment option to adults in Europe with moderate AD for whom standard topical therapies have failed,” said Lee Heeson, Executive Vice President and Head of Incyte International. “If approved by the European Commission, Opzelura could help address an important gap for patients who have limited treatment options when TCSs and TCIs are inadequate or inappropriate.” The positive CHMP o
Datroway ® Recommended for Approval in the EU by CHMP as First-Line Treatment for Patients with Metastatic Triple Negative Breast Cancer Who Are Not Candidates for Immunotherapy26.6.2026 14:00:00 EEST | Press release
Datroway® (datopotamab deruxtecan) has been recommended for approval in the European Union (EU) as monotherapy for the first-line treatment of adult patients with unresectable or metastatic triple negative breast cancer (TNBC) who are not candidates for PD-1/PD-L1 inhibitor therapy. Datroway is a specifically engineered TROP2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from the TROPION-Breast02phase 3 trial, which werepresented at the 2025 European Society for Medical Oncology Congress and published in Annals of Oncology. The recommendation will now be reviewed by the European Commission, which has the authority to grant marketing authorizations for medicines in the EU. In TROPION-Breast02, Datroway demonstrated a
DAYBU ® (trofinetide) Recommended for Approval in the European Union by CHMP26.6.2026 13:49:00 EEST | Press release
Acadia Pharmaceuticals Inc. (Nasdaq: ACAD) today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has adopted a positive opinion following a re-examination procedure, recommending the granting of a marketing authorization for DAYBU® (trofinetide) for the treatment of neurobehavioral symptoms of Rett syndrome in adults and pediatric patients aged five years and older. If granted marketing authorization by the European Commission, DAYBU® would be the first therapy approved for this indication in the European Union (EU). “The CHMP’s positive opinion for DAYBU® is an important milestone in our mission to bring this innovative therapy to the EU, where there are no therapies specifically approved for the neurobehavioral symptoms of this devastating condition," said Catherine Owen Adams, Acadia’s Chief Executive Officer. “Our commitment is to make a meaningful difference in the lives of patients, caregivers, and the wider Rett com
HTEC Showcases Lakebase Branching at Databricks’ Data & AI Summit26.6.2026 12:18:00 EEST | Press release
HTEC, the global technology and AI engineering firm headquartered in Silicon Valley, last week showcased how it used Lakebase data branching to enable faster development, safer operations, and new possibilities for data-driven organizations operating in highly regulated environments. The Solution was developed in collaboration with a leading risk and compliance technology provider who serves financial institutions. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260626875859/en/ HTEC, the global technology and AI engineering firm headquartered in Silicon Valley, last week showcased how it used Lakebase data branching to enable faster development, safer operations, and new possibilities for data-driven organizations operating in highly regulated environments. Solving Critical Development Bottlenecks in Regulated Environments At the core of the collaboration was a shared challenge: how to enable modern data workflows in an envi
Stallergenes Greer Named One of Switzerland’s Best Managed Companies for 202626.6.2026 11:28:00 EEST | Press release
Stallergenes Greer, a global leader in allergy care, has been recognised for its overall business performance, company culture, and sustained growth by receiving the prestigious 2026 Switzerland’s Best Managed Companies award. The 2026 Best Managed Companies programme award winners are among Switzerland’s best private companies. The awards are derived from Deloitte’s global Best Managed Companies awards programme, an internationally recognised programme that evaluates businesses based on their leadership in the areas of strategy, culture and commitment, capabilities, innovation, governance and financial performance. Applicants are evaluated by an independent jury of experts. The evaluation of the Switzerland awards is based on more than 30 years of observed practice from the global awards programme that has been rolled out in 50+ countries worldwide. This recognition reflects Stallergenes Greer's consistent ability to deliver on its strategic vision while maintaining the operational di
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom